NCT06938971

Brief Summary

The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
48mo left

Started May 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
May 2025May 2030

First Submitted

Initial submission to the registry

March 31, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

April 22, 2025

Completed
24 days until next milestone

Study Start

First participant enrolled

May 16, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2030

Last Updated

May 13, 2026

Status Verified

May 1, 2026

Enrollment Period

2 years

First QC Date

March 31, 2025

Last Update Submit

May 8, 2026

Conditions

Keywords

ExercisePhysical activityMetastatic colorectal cancerColorectal cancerEndurance trainingOncologyChemotherapy

Outcome Measures

Primary Outcomes (1)

  • Health-related quality of life

    The difference in means of the average global health-related quality of life score in intervention versus control, regardless of intervention compliance; disease progression; cancer treatment discontinuation or dose-modifications; changes in initially scheduled cancer treatment; and engagement in alternative cancer care, in physical activity, structured exercise training, or municipality-based cancer rehabilitation. Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Every 3 weeks from randomization until post-intervention (18 weeks), withdrawal of consent to participate, or death (whichever occurs first)

Secondary Outcomes (28)

  • Health-related quality of life

    Randomization and 3, 6, 9, 12, 15, and 18 weeks after randomization or until withdrawal of consent to participate, or death (whichever occurs first). Followed-up at 36, 52, 104, and 156 weeks after randomization.

  • Colorectal cancer-specific symptoms

    Randomization and 3, 6, 9, 12, 15, and 18 weeks after randomization or until withdrawal of consent to participate, or death (whichever occurs first). Followed-up at 36, 52, 104, and 156 weeks after randomization.

  • Cancer related fatigue

    Randomization and 3, 6, 9, 12, 15, and 18 weeks after randomization or until withdrawal of consent to participate, or death (whichever occurs first). Followed-up at 36, 52, 104, and 156 weeks after randomization.

  • Patient-reported symptomatic adverse events

    7 days after every second cycle of treatment, starting from the second cycle. Each cycle is 2-3 weeks, depending on the regimen.

  • Serious adverse events

    From randomization to 20 weeks after randomization

  • +23 more secondary outcomes

Study Arms (2)

Control

NO INTERVENTION

Participants allocated to the control group will receive standard care. No restrictions regarding physical activity will be imposed.

Exercise training

EXPERIMENTAL

Participants allocated to the exercise intervention group will receive standard care plus an exercise intervention. The exercise intervention will of consist moderate-to-high intensity supervised and unsupervised home-based exercise training (bicyling, walking, or running) 5 times/week for 18 weeks. After the initial 18-week intervention period, participants will be given the option to continue the intervention until week 162.

Other: Exercise training

Interventions

Participants allocated to the exercise intervention group will receive standard care plus an exercise intervention. The exercise intervention will consist moderate-to-high intensity supervised and unsupervised home-based exercise training (bicyling, walking, or running) 5 times/week for 18 weeks.

Exercise training

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Adults (≥18 years of age) schduled to undergo first-line chemotherapy for the treatment of metastatic colorectal cancer.

You may not qualify if:

  • Pregnancy.
  • A life expectancy of \< 6 months.
  • Absolute contraindications to maximal exercise, as per the recommendations by the Danish Society of Cardiology.
  • ECOG (Eastern Cooperative Oncology Group) performance status \> 2.
  • Inability to understand the Danish or English language.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Centre for Physical Activity Research, Copenhagen Univerisity Hospital - Rigshospitalet

Copenhagen, 2100, Denmark

RECRUITING

Herlev and Gentofte Hospital

Herlev, 2730, Denmark

RECRUITING

North Zealand University Hospital, Hillerød

Hillerød, 3400, Denmark

RECRUITING

Zealand University Hospital, Roskilde

Roskilde, 4000, Denmark

RECRUITING

MeSH Terms

Conditions

Colorectal NeoplasmsMotor ActivityNeoplasms

Interventions

Exercise

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Group Leader

Study Record Dates

First Submitted

March 31, 2025

First Posted

April 22, 2025

Study Start

May 16, 2025

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2030

Last Updated

May 13, 2026

Record last verified: 2026-05

Locations